NEWS
UK Study Details Skin Cancer Risks for MPN Patients
MPN NEWS | March 15, 2024
Several studies have confirmed the association of ruxolitinib (a JAK inhibitor) with increased risk of non-melanoma skin cancers (NMSCs). A study published in a January 2024 issue of the journal Blood reports on just how serious the risks might be, specifically among patients living with essential thrombocythemia (ET), polycythemia vera (PV), and myelofibrosis (MF). And… Read More »UK Study Details Skin Cancer Risks for MPN Patients
Who Develops Which MPN and Why?
MPN NEWS | March 15, 2024
Jyoti Nangalia, PhD, Wellcome Sanger Institute It is known that JAK2 mutations are found in “healthy” people around the world, particularly in older individuals. Most of them don’t acquire characteristics of myeloproliferative neoplasms (MPNs). The question is why do some people with the mutation develop an MPN while others don’t. Researchers from the Wellcome… Read More »Who Develops Which MPN and Why?
Cancer Words Matter
MPN NEWS | February 20, 2024
Cancer is such a powerful word that it is often referred to as “The Big C” and comes with a loaded associated vocabulary, including words that can have both empowering or disturbing triggers, depending on the individual hearing it. Not many people go through life without being touched by cancer in some way. This means… Read More »Cancer Words Matter
Cardiovascular Risk and MPNs
MPN NEWS | February 20, 2024
While cardiovascular events often accompany MPNs and contribute significantly to morbidity and mortality, the reasons remained unclear until research offered some insight in recent years. Greater understanding about why and how blood cancers have connections to cardiovascular complications lays the groundwork to using this information to better assess and manage risk factors in MPN patients,… Read More »Cardiovascular Risk and MPNs
How MPNs Progress to AML and How to Stop It
MPN NEWS | February 20, 2024
Thrive Award Spotlight: John Crispino, St. Jude Children’s Research HospitalCo-PI – Ayalew Tefferi, Mayo Clinic, MN Aberrant Megakaryopoiesis in the MPNs According to Leukemia & Lymphoma Society, although MPN patients can be stable for decades, they face a significant risk of having their disease advance to a more immediately life-threatening blood cancer, acute myeloid leukemia… Read More »How MPNs Progress to AML and How to Stop It
Caregiver Brings Unique Perspective to MPNRF Patient Impact Council
MPN NEWS | January 16, 2024
Learning More About MPN Cell Metabolism to Help Identify Novel Points of MPN Therapy
MPN NEWS | January 16, 2024
Shannon Elf, PhD, University of Utah Huntsman Cancer Institute The metabolic landscape of MPNs is an extremely understudied area in the field. Solid tumor treatment has benefited tremendously from studying cellular metabolism in a number of cancers, and Dr. Shannon Elf, a junior investigator at University of Chicago, believes the same can be… Read More »Learning More About MPN Cell Metabolism to Help Identify Novel Points of MPN Therapy
What’s Next?
MPN NEWS | January 16, 2024
The world of myeloproliferative neoplasms (MPNs) has witnessed a surge in scientific breakthroughs. From detecting genetic drivers as early as in the fetus to the unprecedented pace of new drug approvals, the momentum is changing how this family of blood cancers is understood and managed. Increased attention and industry investment have led to a growing number of treatment… Read More »What’s Next?
Our Own MPN Heroes
MPN NEWS | December 22, 2023
We celebrate two members of our Board of Directors recently named MPN Heroes during the Annual Meeting of the American Society of Hematology (ASH). Dr. Andrew Schafer is director of the Richard T. Silver, M.D. MPN Center at Weill Cornell in NYC and a valued scientific advisor to MPN Research Foundation for many years. https://www.youtube.com/watch?v=9_yNLqJKHJU… Read More »Our Own MPN Heroes
MPN News to Expect at ASH 2023
MPN NEWS | November 29, 2023
Each year at the Annual Meeting of The American Society of Hematology (ASH), there are more MPN research and clinical trial reports. This year, some unique highlights include 16 topics we find notable, along with many others with a potential connection to MPNs. Artificial intelligence (AI) to differentiate between essential thrombocythemia and prefibrotic primary myelofibrosis. … Read More »MPN News to Expect at ASH 2023